Top-Rated Stocks NASDAQ:PNT POINT Biopharma Global - PNT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding POINT Biopharma Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.10 +0.15 (+1.89%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$7.81▼$8.3350-Day Range$6.49▼$8.0052-Week Range$5.22▼$10.98Volume1.49 million shsAverage Volume593,213 shsMarket Capitalization$842.64 millionP/E RatioN/ADividend YieldN/APrice Target$16.13 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media POINT Biopharma Global MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside99.1% Upside$16.13 Price TargetShort InterestBearish10.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 2 Articles This WeekInsider TradingAcquiring Shares$229,158 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.48) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector522nd out of 1,030 stocksPharmaceutical Preparations Industry262nd out of 502 stocks 3.5 Analyst's Opinion Consensus RatingPOINT Biopharma Global has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.13, POINT Biopharma Global has a forecasted upside of 99.1% from its current price of $8.10.Amount of Analyst CoveragePOINT Biopharma Global has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.01% of the float of POINT Biopharma Global has been sold short.Short Interest Ratio / Days to CoverPOINT Biopharma Global has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in POINT Biopharma Global has recently increased by 5.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPOINT Biopharma Global does not currently pay a dividend.Dividend GrowthPOINT Biopharma Global does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PNT. Previous Next 2.9 News and Social Media Coverage News SentimentPOINT Biopharma Global has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for POINT Biopharma Global this week, compared to 1 article on an average week.Search Interest4 people have searched for PNT on MarketBeat in the last 30 days. MarketBeat Follows5 people have added POINT Biopharma Global to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, POINT Biopharma Global insiders have bought more of their company's stock than they have sold. Specifically, they have bought $229,158.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders18.70% of the stock of POINT Biopharma Global is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.77% of the stock of POINT Biopharma Global is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for POINT Biopharma Global are expected to decrease in the coming year, from ($0.48) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of POINT Biopharma Global is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of POINT Biopharma Global is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPOINT Biopharma Global has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About POINT Biopharma Global (NASDAQ:PNT) StockPOINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.Read More Receive PNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter. Email Address PNT Stock News HeadlinesFebruary 2, 2023 | americanbankingnews.comBrokerages Set POINT Biopharma Global Inc. (NASDAQ:PNT) PT at $16.13January 18, 2023 | seekingalpha.comPNT POINT Biopharma Global Inc.February 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 12, 2023 | finance.yahoo.comWe Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business GrowthDecember 20, 2022 | finance.yahoo.comPOINT Biopharma Announces Closing of Agreements with Lantheus HoldingsDecember 16, 2022 | finance.yahoo.comWhen Will POINT Biopharma Global Inc. (NASDAQ:PNT) Turn A Profit?November 29, 2022 | finance.yahoo.comPOINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with ImmunotherapyNovember 29, 2022 | seekingalpha.comLantheus: Sell Thesis Missing These Key FactorsFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 28, 2022 | seekingalpha.comLantheus Holdings: May Be Time To Buy After Big CorrectionNovember 22, 2022 | benzinga.com311K Reasons To Be Bullish On POINT Biopharma Global StockNovember 15, 2022 | markets.businessinsider.comAnalyst Ratings for POINT Biopharma GlobalNovember 14, 2022 | finance.yahoo.comLantheus-POINT Biopharma Ink Strategic Collaboration For Cancer ProgramsNovember 14, 2022 | seekingalpha.comPoint Biopharma slumps 35% on license deal with Lantheus for cancer drugsNovember 14, 2022 | finance.yahoo.comPOINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus HoldingsNovember 11, 2022 | msn.comHow Much Upside is Left in POINT Biopharma Global Inc. (PNT)? Wall Street Analysts Think 212%November 11, 2022 | morningstar.comNorth American Morning Briefing: Fed Hopes, China -2-November 10, 2022 | msn.comWhy Earnings Season Could Be Great for POINT Biopharma (PNT)October 26, 2022 | finance.yahoo.comWall Street Analysts Think POINT Biopharma Global Inc. (PNT) Could Surge 235%: Read This Before Placing a BetOctober 17, 2022 | finance.yahoo.comPOINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM’s Annual CongressOctober 17, 2022 | finance.yahoo.comCalculating The Intrinsic Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)October 10, 2022 | investing.comUPDATE: Oppenheimer Starts POINT Biopharma Global Inc. at OutperformSeptember 16, 2022 | finance.yahoo.comPOINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common StockSeptember 14, 2022 | marketwatch.comPOINT Biopharma Shares Slide After Public Offering >PNTSeptember 14, 2022 | nasdaq.comPOINT Biopharma Global Prices Public Offering Of 13.90 Mln Shares At $9.00/shrSeptember 13, 2022 | finance.yahoo.comPOINT Biopharma Prices Public Offering of Common StockSeptember 13, 2022 | finance.yahoo.comPOINT Biopharma Announces Proposed Public Offering of Common StockSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter. Email Address PNT Company Calendar Last Earnings11/14/2022Today2/02/2023Next Earnings (Estimated)3/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PNT CUSIPN/A CIK1811764 Webwww.pointbiopharma.com Phone317-543-9957FaxN/AEmployees72Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.13 High Stock Price Forecast$22.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+99.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,900,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-31.08% Return on Assets-29.43% Debt Debt-to-Equity RatioN/A Current Ratio17.84 Quick Ratio17.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.83 per share Price / Book2.86Miscellaneous Outstanding Shares104,030,000Free Float84,572,000Market Cap$842.64 million OptionableNot Optionable Beta0.12 Key ExecutivesMr. Allan Charles Silber (Age 72)Exec. Chairman Comp: $677.8kDr. Joe A. McCann Ph.D. (Age 44)CEO & Director Comp: $740.31kDr. Neil E. Fleshner FRCSC (Age 59)M.D., M.PH, Chief Medical Officer & Director Comp: $227.5kMs. Jessica D. Jensen M.P.H. (Age 41)MPH, Exec. VP of Clinical Devel. Comp: $541.59kMr. Bill Demers B.B.A. (Age 64)F.C.A., FCPA, Chief Financial Officer Ms. Justyna Kelly M.Sc. (Age 37)Chief Operating Officer Ms. Donna Husack B.A.VP of HRMr. Ari ShomairVP of Corp. Affairs & Chief of StaffDr. Myra Rosario Herle Ph.D.R.Ph., Exec. VP of Regulatory AffairsDr. Matthew P. Vincent J.D.Ph.D., Sr. VP of Bus. Devel.More ExecutivesKey CompetitorsBioXcel TherapeuticsNASDAQ:BTAIIDEAYA BiosciencesNASDAQ:IDYALyell ImmunopharmaNASDAQ:LYELJanux TherapeuticsNASDAQ:JANXBicycle TherapeuticsNASDAQ:BCYCView All CompetitorsInsiders & InstitutionsProShare Advisors LLCBought 10,999 shares on 2/2/2023Ownership: 0.011%Zurcher Kantonalbank Zurich Cantonalbank Bought 2,633 shares on 2/1/2023Ownership: 0.011%Bank of New York Mellon CorpBought 21,159 shares on 12/8/2022Ownership: 0.217%Joe A MccannBought 2,160 shares on 11/29/2022Total: $14,342.40 ($6.64/share)California State Teachers Retirement SystemBought 20,998 shares on 11/21/2022Ownership: 0.084%View All Insider TransactionsView All Institutional Transactions PNT Stock - Frequently Asked Questions Should I buy or sell POINT Biopharma Global stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PNT shares. View PNT analyst ratings or view top-rated stocks. What is POINT Biopharma Global's stock price forecast for 2023? 9 Wall Street research analysts have issued 12-month price targets for POINT Biopharma Global's shares. Their PNT share price forecasts range from $10.00 to $22.00. On average, they predict the company's share price to reach $16.13 in the next year. This suggests a possible upside of 97.6% from the stock's current price. View analysts price targets for PNT or view top-rated stocks among Wall Street analysts. How have PNT shares performed in 2023? POINT Biopharma Global's stock was trading at $7.29 at the start of the year. Since then, PNT shares have increased by 11.9% and is now trading at $8.16. View the best growth stocks for 2023 here. When is POINT Biopharma Global's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 24th 2023. View our PNT earnings forecast. How were POINT Biopharma Global's earnings last quarter? POINT Biopharma Global Inc. (NASDAQ:PNT) announced its earnings results on Monday, November, 14th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. What is POINT Biopharma Global's stock symbol? POINT Biopharma Global trades on the NASDAQ under the ticker symbol "PNT." Who are POINT Biopharma Global's major shareholders? POINT Biopharma Global's stock is owned by many different retail and institutional investors. Top institutional shareholders include Zurcher Kantonalbank Zurich Cantonalbank (0.01%), ProShare Advisors LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allan C Silber, Joe A Mccann, Jonathan R Goodman, Neil E Fleshner and Yael Margolin. View institutional ownership trends. How do I buy shares of POINT Biopharma Global? Shares of PNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is POINT Biopharma Global's stock price today? One share of PNT stock can currently be purchased for approximately $8.16. How much money does POINT Biopharma Global make? POINT Biopharma Global (NASDAQ:PNT) has a market capitalization of $848.88 million. The company earns $-45,900,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. How can I contact POINT Biopharma Global? POINT Biopharma Global's mailing address is 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116. The official website for the company is www.pointbiopharma.com. The company can be reached via phone at 317-543-9957. This page (NASDAQ:PNT) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.